Gilteritinib Reduces FLT3 Expression in Acute Myeloid Leukemia Cells
{{output}}
Acute myeloid leukemia (AML) is a genetically diverse and challenging malignancy, with mutations in the FLT3 gene being particularly common and deleterious. Gilteritinib, a potent FLT3 inhibitor, has been approved by the U.S. Food and Drug Administration (FDA)... ...
